Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery by Ramos Izquierdo, Ricard et al.
Ramos et al. BMC Pulm Med           (2021) 21:75  
https://doi.org/10.1186/s12890-021-01446-1
ARTICLE
Prognostic value of the preoperative 
lymphocyte-to-monocyte ratio for survival 
after lung cancer surgery
Ricard Ramos1,6*, Ivan Macía1,6, Arturo Navarro‑Martin2, Carlos Déniz1, Francisco Rivas1, Anna Ureña1, 
Cristina Masuet‑Aumatell3, Camilo Moreno1, Ernest Nadal4,5 and Ignacio Escobar1
Abstract 
Background: The aim of this study was to assess the effect of the lymphocyte‑to‑monocyte ratio (LMR), neutrophil‑
to‑lymphocyte ratio and platelet‑to‑lymphocyte ratio on overall survival and disease‑free survival in patients with 
lung cancer treated with radical surgery.
Methods: We performed a retrospective review of patients with lung cancer who prospectively underwent radical 
resection between 2004 and 2012. Blood samples were taken as part of the preoperative workup. The inflammatory 
markers studied were absolute values of lymphocytes, monocytes, neutrophils and platelets, with subsequent calcula‑
tion of ratios. Median follow‑up was 52 months.
Results: Two hundred and sixty‑eight patients underwent surgery, of whom 218 (81.3%) were men. Mean age 
was 62.9 ± 8.7 years. A lymphocyte‑to‑monocyte ratio ≥ 2.5 was independently associated with longer disease‑free 
survival (hazard ratio [HR] 0.476 (0.307–0.738), p = 0.001) and longer overall survival (HR, 0.546; 95% CI: 0.352–0.846; 
p = 0.007), in models adjusted for age, sex, stage, and type of resection. No other systemic inflammatory marker 
showed a significant association.
Conclusion: Preoperative LMR is an independent prognostic factor of overall survival and recurrence‑free survival in 
patients with surgically‑resected early stage lung cancer.
Keywords: Inflammation, Lung cancer, Survival, Lymphocyte‑to‑monocyte ratio, Neutrophil‑to‑lymphocyte ratio, 
Platelet‑to‑lymphocyte ratio
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Background
Lung cancer causes the most cancer-related deaths 
worldwide. Increasing knowledge of tumour biology and 
multimodal treatments have helped improve treatment, 
and several prognostic factors exist, but overall survival 
remains poor, except in stage I, for which survival ranges 
between 60 and 80% [1, 2].
Prognostic factors related not to the tumour itself but 
to the patient’s general health status have been studied, 
including nutritional status and inflammatory status. 
Nutritional status is a prognostic factor in patients with 
lung cancer [3, 4], and our group has confirmed that 
nutritional status affects survival and postoperative out-
comes in patients with lung cancer who undergo surgical 
resection [5].
Another prognostic factor that has been associated 
with survival and complications is inflammatory sta-
tus. Multiple parameters can be used to determine the 
inflammatory status of a patient with cancer, but blood 
markers that are often used in preoperative assessment 
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due to being simple to obtain are C reactive protein, 
absolute values of neutrophils, lymphocytes, mono-
cytes and platelets, and the ratios of neutrophils to lym-
phocytes, platelets to lymphocytes and lymphocytes to 
monocytes. Certain levels of these parameters are asso-
ciated with better or worse survival in various cancers, 
including lung cancer [6, 7].
The European Lung Cancer Working Group confirmed 
that patients with a high neutrophil count had worse sur-
vival [8]. Likewise, a high neutrophil-to-lymphocyte ratio 
and platelet-to-lymphocyte ratio are markers of worse 
prognosis in patients with cancer in general and particu-
larly in lung cancer [9, 10]; however, within the inflam-
matory response, lymphocytes and monocytes both play 
an important role in postoperative outcomes following 
lung cancer resection [11, 12].
In this study, we assessed the effect of these systemic 
inflammatory markers on overall survival (OS) and dis-
ease-free survival (DFS) in patients with non-small cell 
lung cancer (NSCLC) who underwent radical resection 
with follow-up of at least 5 years.
Methods
Study population
We retrospectively reviewed a cohort of 653 patients who 
were treated with radical lung resection between Janu-
ary 2004 and December 2012. Patients with a history of 
systemic inflammatory disease, concomitant active infec-
tion, neoadjuvant treatment, preoperative stage ≥ T3, 
preoperative stage ≥ N1, patients lost to follow-up, 
or those for whom preoperative blood tests were not 
available were excluded (Fig. 1). Finally, we included 268 
patients diagnosed with early clinical stage non-small cell 
lung cancer who underwent anatomic pulmonary resec-
tion with systematic lymph node dissection.
All patients underwent the same preoperative workup 
which included physical examination, full blood count 
and renal function tests, bronchoscopy, pulmonary func-
tion tests with diffusion studies, computed tomogra-
phy (CT) and positron-emission tomography/computed 
tomography (PET-CT). All patients signed an informed 
consent form and the study was approved by the Institu-
tional Review Board.
Study variables
The variables studied were age, sex, comorbidities (smok-
ing, diabetes mellitus, ischaemic heart disease, chronic 
obstructive pulmonary disease, and hypertension), type 
of surgery performed, pathological stage, tumour histol-
ogy, disease-free survival and overall survival. The study 
aims did not include the association between these mark-
ers and postoperative complications.
The lymphocyte-to-monocyte ratio (LMR), neutrophil-
to-lymphocyte ratio (NLR), and platelet-to-lymphocyte 
ratio (PLR) were calculated from the absolute neutrophil, 
platelet, monocyte and lymphocyte counts from routine 
preoperative testing performed 1–2 weeks before surgery 
at the same hospital.
Follow‑up
Routine follow-up was carried out at 1 month after sur-
gery and included a full panel of blood tests and chest 
Fig. 1 Flow chart of patient selection
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X-ray, then every 6  months with CT chest for the first 
3  years, with annual checks thereafter, as per hospital 
protocol. If recurrence was suspected after surgery, the 
relevant tests, eg PET-CT, MRI brain, were requested 
according to the clinical scenario. Recurrences were 
classified as locoregional or distant metastases based on 
imaging. Locoregional recurrence was defined as recur-
rence in mediastinal or hilar lymph nodes or ipsilateral 
lung. Other recurrences were defined as distant metasta-
ses. All patients were seen by specialists and discussed by 
the multidisciplinary team to decide on treatment plan-
ning. Diagnosis of recurrence or distant metastases was 
evaluated and confirmed in the multidisciplinary unit.
Statistical analysis
A descriptive analysis of the sample was performed as 
frequency and percentage for qualitative variables, and 
mean and standard deviation for quantitative variables 
if they followed a normal distribution (Kolmogorov–
Smirnov, p value > 0.05), or median and interquartile 
range if not. Subsequently, Kaplan–Meier survival analy-
sis was performed, and variables that were clinically rel-
evant and statistically significant (Log rank p value < 0.05) 
and that did not show interaction between them were 
included in Cox regression. A receiver operating charac-
teristics (ROC) analysis was performed to calculate the 
NLR, PLR, and LMR values that would have the greatest 
sensitivity and specificity. The statistical software SPSS v 
16.0 was used.
Results
Two hundred and sixty-eight patients were included in 
the study, of whom 218 (81.3%) were men. The mean age 
was 62.9 ± 8.7  years. Clinical, surgical, and pathologi-
cal features and blood values of the study population are 
shown in Table  1. Twenty-five patients (9.2%) received 
tumour-specific adjuvant treatment. The median follow-
up time was 52  months. One hundred patients (37.3%) 
developed recurrence, of whom 74 (27.6%) had distant 
metastases and 26 (9.7%) had locoregional recurrence. 
Twelve patients (4.5%) developed second primary lung 
tumours and underwent new radical surgery. One hun-
dred and fifty-nine (57.3%) patients were still alive at the 
end of follow-up; 109 (42.7%) patients died.
Following ROC analysis, the values with the greatest 
sensitivity and specificity were 2.5 for NLR and LMR and 
150 for PLR. Disease-free survival and OS were evalu-
ated after splitting patients according to these proposed 
maker levels (Table  2). An LMR ≥ 2.5 was a clear prog-
nostic factor for higher overall survival and lower recur-
rence in patients with surgically-resected lung cancer 
(p = 0.001) (Figs. 2, 3). On univariate analysis, age, patho-
logical stage and LMR ≥ 2.5 were significantly associated 
with higher disease-free survival (HR, 0.444; 95% CI 
0.289–0.683; p = 0.001). These variables remained sta-
tistically significant on multivariate analysis (HR, 0.476; 
Table 1 Clinical, surgical, pathological and  inflammatory 
parameters for the study population
COPD chronic obstructive pulmonary disease, LMR lymphocyte-to-monocyte 
ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
N (%) 
or mean ± SD 
or median (range)
Males 268 (81.3%)
Age (years) 62.9 ± 8.7
Smoker 205 (76.5%)
Diabetes mellitus 57 (21.3%)





 Lobectomy 224 (83.6%)
 Pneumonectomy 14 (5.2%)
 Sub‑lobar resection 38 (11.2%)
Pathologic stage
 Ia/Ib 173 (64.5%)
 IIa/IIb 74 (27.6%)
 IIIa/IIIb 19 (7.1%)
 IV 2 (0.8%)
Histological type
 Adenocarcinoma 168 (62.7%)
 Squamous cell carcinoma 79 (29.5%)
 Large cell carcinoma 18 (6.7%)
 Other 3 (1.1%)
Neutrophils, × 109/L 4.47 (1.63)
Lymphocytes, × 109/L 2.14 (1.59)
Monocytes, × 109/L 0.57 (0.20)




Table 2 Distribution of patients according to LMR
LMR lymphocyte-to-monocyte ratio
Study population, n: 268 LMR < 2.5 LMR ≥ 2.5
No. of patients 47 221
No. of patients who died during the follow‑up 
period
28 81
No. of patients who died or had recurrence dur‑
ing the follow‑up period
35 107
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95% CI 0.307–0.738; p = 0.001; Table  3) after adjusting 
for age, sex, pathological stage and histology.
Regarding overall survival, univariate analysis showed 
that age, pathological stage and LMR ≥ 2.5 were asso-
ciated with better overall survival (HR, 0.488; 95% CI 
0.317–0.751; p = 0.001). These variables were also sig-
nificant on multivariate analysis (HR, 0.546; 95% CI 
0.352–0.846; p = 0.007; Table  4) after adjusting for age, 
sex, pathological stage and histology. NLR and PLR were 
not found to be prognostic factors for overall survival or 
disease-free survival.
Discussion
The association between inflammation and cancer was 
first described years ago and has been the subject of 
much study. O’Callaghan et al. [13] described the role of 
0 12 24 36 48 60 72 84 96 108 120 132 144
LMR<2,5 % 89.4% 80.9% 74.5% 61.6% 52.8% 42.2% 33.8% 24.1% 24.1% 24.1% 24.1% 24.1% 
No of 
events
0 5 9 12 18 21 24 26 28 28 28 28 28
No at 
risk
47 42 38 35 27 15 11 8 5 4 2 1 1
LMR>=2,5 % 95.9% 88.6% 82.6% 75.7% 71.4% 67.3% 63.0% 59.1% 55.9% 50.9% 36.1% ---
No of 
events
9 25 38 53 61 66 70 73 75 77 80 ---
No at 
risk
219 210 193 179 156 107 73 57 41 24 15 5 ---
Fig. 2 Kaplan–Meier analysis of overall survival (OS) based on LMR
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inflammation in the etiopathogenesis of lung cancer, and 
multiple studies have confirmed the prognostic value of 
inflammation in lung cancer outcomes, for both local and 
advanced disease [10, 14].
Our study included 268 patients who underwent resec-
tion and prospective follow-up for at least 5  years, and 
demonstrates that an LMR ≥ 2.5 is an independent posi-
tive prognostic factor for disease-free survival and overall 
survival. Although this ratio has not been studied exten-
sively in cancer and particularly bronchogenic cancer, our 
findings are in line with those obtained by other groups. 
Xia et al. [15], in 439 patients with stage I NSCLC, dem-
onstrated a positive association between LMR and over-
all survival and a greater risk of distal metastases with 
lower LMR. However, Asian populations may behave 
differently from European populations in terms of blood 
0 12 24 36 48 60 72 84 96 108 120 132 144
LMR<2.5 % 82.6% 71.6% 60.4% 48.3% 37.2% 31.9% 20% 20% 20% --- --- ---
No of 
events
8 13 18 23 26 27 29 29 29 --- --- ---
No at 
risk
47 38 32 27 17 9 6 3 3 1 --- --- ---
LMR>=2.5 % 93.0% 81.2% 74.0% 70.5% 66.1% 62.8% 60.1% 56.8% 54.6% 50.7% 50.7% ---
No of 
events
15 40 55 62 69 72 74 76 77 78 78 ---
No at 
risk
219 199 170 150 132 85 52 39 29 18 11 3 ---
Fig. 3 Kaplan–Meier analysis of disease‑free survival (DFS) based on LMR
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markers, so their results will need to be validated in a 
Western population.
In 2018, Chen et al. [16] published a series of 577 sur-
gical patients in stage IB NSCLC who had undergone 
pneumonectomy. They found that LMR and PLR were 
independent prognostic factors for OS. In our series, 
LMR was an independent prognostic factor for OS and 
DFS. However, we did not find a statistically significant 
association for PLR as a prognostic factor. One explana-
tion could be that the patients requiring pneumonectomy 
are usually patients with larger tumours or with greater 
intrapulmonary lymph node involvement, so they are 
likely to have higher baseline levels of inflammation. In 
our study only 5.2% of the patients had undergone pneu-
monectomy, while 100% of those in the study by Chen 
et al. had undergone pneumonectomy, with pleural inva-
sion in 39% of the cases.
The immunological basis for our findings is that 
lymphoid cells play a primordial role in the control, 
proliferation, and migration of tumour cells [17]. In cer-
vical cancer, it has been observed that lymphocytes act as 
essential components of the immune response, and low 
levels of lymphocytes in the peripheral blood and tumour 
stroma lead to a weaker immune response against the 
Table 3 Univariate and  multivariate analysis of  disease-
free-survival (DFS)
LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR 
platelet-to-lymphocyte ratio
* Linear trend p value
Covariables Hazard ratio 95% CI p value
Univariate analysis
PLR ≥ 150 0.986 0.654–1.488 0.948
NLR ≥ 2.5 1.203 0.821–1.761 0.343
LMR ≥ 2.5 0.444 0.289–0.683 0.001
Age 1.018 0.996–1.040 0.112
Sex (female) 0.970 0.595–1.579 0.901
Pathological stage 0.051*
 I 1.000
 II 1.686 1.126–2.526 0.011
 III 1.793 0.812–3.958 0.148
 IV 2.536 0.350–18.380 0.357
Histological type 0.219*
 Adenocarcinoma 1.000
 Squamous cell carcinoma 0.618 0.384–0.995 0.048
 Large cell carcinoma 0.792 0.381–1.646 0.532
 Other 0.568 0.138–2.343 0.434
Multivariate analysis
LMR ≥ 2.5 0.476 0.307–0.738 0.001
Age 1.029 1.005–1.054 0.017
Sex
 Male 1.000
 Female 1.171 0.693–1.977 0.556
Pathological stage 0.027*
 I 1.000
 II 1.779 1.174–2.695 0.007
 III 1.878 0.848–4.162 0.120
 IV 3.101 0.406–23.695 0.275
Histological type 0.053*
 Adenocarcinoma 1.000
 Squamous cell carcinoma 0.527 0.322–0.862 0.011
 Large cell carcinoma 0.619 0.294–1.301 0.205
 Other 0.541 0.127–2.306 0.407
Table 4 Univariate and  multivariate analysis of  overall 
survival
LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR 
platelet-to-lymphocyte ratio
* Linear trend p value
Covariables Hazard ratio 95% CI p value
Univariate analysis
PLR ≥ 150 1.151 0.772–1.715 0.494
NLR ≥ 2.5 1.175 0.806–1.714 0.401
LMR ≥ 2.5 0.488 0.317–0.751 0.001
Age 1.037 1.013–1.060 0.002
Sex (female) 0.831 0.481–1.436 0.507
Pathological stage 0.026*
 Stage I 1.000
 Stage II 1.718 1.148–2.571 0.009
 Stage III 1.980 0.975–4.017 0.059
 Stage IV 2.296 0.317–16.631 0.411
Histological type 0.999*
 Adenocarcinoma 1.000
 Squamous cell carcinoma 0.991 0.651–1.509 0.967
 Large cell carcinoma 1.041 0.518–2.091 0.909
 Other 0.986 0.135–7.190 0.989
Multivariate analysis
LMR ≥ 2.5 0.546 0.352–0.846 0.007
Age 1.041 1.017–1.066 0.001
Sex
 Male 1.000 0.966
 Female 1.013 0.564–1.819
Pathological stage 0.013*
 I 1.000
 II 1.783 1.179–2.697 0.006
 III 2.144 1.047–4.389 0.037
 IV 4.083 0.521–31.995 0.180
Histological type 0.830*
 Adenocarcinoma 1.000
 Squamous cell carcinoma 0.812 0.525–1.255 0.348
 Large cell carcinoma 0.923 0.457–1.864 0.824
 Other 0.929 0.122–7.056 0.943
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cancer cell [18]. In contrast, the presence of high levels 
of monocytes and their derivatives induces immuno-
suppression and tumour neoangiogenesis. In addition, 
intratumour macrophages, derived directly from tissue 
monocytes, facilitate tumour cell migration by secret-
ing mediators that degrade the extracellular matrix and 
attract more intratumour monocytes/macrophages, lead-
ing to greater tumour aggressiveness both locally and dis-
tally [19–22].
In nonsurgical treatments such as stereotactic radiation 
therapy, several groups have described the effect of NLR 
and PLR in terms of local recurrence. Canon et  al. [10] 
found that PLR should be used as a prognostic factor for 
DFS. In our study, we did not find such an association, but 
we must bear in mind that the inflammatory status in the 
nonsurgical population is probably different: although in 
some cases patients decline surgery, in many cases they 
are unsuitable for surgery due to comorbidities.
The interaction between nutritional status, systemic 
inflammatory status and tumour inflammatory status 
plays a key role in postoperative outcomes and progno-
sis in patients with lung cancer [23]. This explains why 
a higher or lower LMR confers better or worse disease 
prognosis among patients undergoing surgery, who theo-
retically will have better long-term outcomes.
The present study has the limitations of being a single-
centre retrospective study. Also, although the preopera-
tive testing used to obtain the ratios was the same for 
all patients, the findings have not been validated in an 
independent cohort. The ideal cut-off point for the ratio 
is difficult to establish, but according to our results, the 
value with the greatest sensitivity and specificity was 2.5; 
values above or below this showed significant differences 
in overall survival and disease-free survival, in line with 
other published studies [15–17, 24, 25].
The number of patients included, more than 200, the 
consistency of the blood testing method, the follow-up 
time and the prospective format of data recording make 
the data presented relevant for future research.
Conclusions
The findings from this study in a cohort of patients who 
underwent surgery for NSCLC confirm that the lym-
phocyte-to-monocyte ratio is a convenient preoperative 
biomarker that could provide valuable information on 
the probability of recurrence and overall survival in this 
population.
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